Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Fineline Cube Aug 21, 2026
Company Drug

Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval

Fineline Cube Aug 24, 2026
Company Drug

Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia

Fineline Cube Aug 24, 2026
Company Deals Policy / Regulatory

Pingshan District and Fosun Pharma Ink Strategic Deal to Boost Biomedical Industry

Fineline Cube Jul 28, 2023

The People’s Government of Pingshan District in Shenzhen has signed a cooperation framework agreement with...

Company Drug

CanSino Biotechnology Receives NMPA Approval for Tetanus Vaccine CS-2047

Fineline Cube Jul 28, 2023

China-based vaccines specialist CanSino Biotechnology Inc., (HKG: 6185) has announced that it has received clinical...

Company Deals

SanReno Therapeutics Partners with WuXi STA for Comprehensive R&D and Manufacturing Services

Fineline Cube Jul 28, 2023

Shanghai-based kidney drug developer SanReno Therapeutics has entered into a partnership with WuXi STA, a...

Company Deals

Chongqing Zhifei Biological Partners with PT Bio Farma for Global Tuberculosis Vaccine Development

Fineline Cube Jul 28, 2023

China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has entered into a global cooperation memorandum...

Company Drug

BRL Medicine Inc. Receives IND Approval for CD19-Targeted CAR-T Therapy BRL-301 from CDE

Fineline Cube Jul 28, 2023

Shanghai-based BRL Medicine Inc. has announced that it has received Investigational New Drug (IND) approval...

Company

Bristol-Myers Squibb Q2 2023 Results Miss Estimates, Full-Year Guidance Revised Downward

Fineline Cube Jul 28, 2023

US pharmaceutical company Bristol-Myers Squibb (BMS; NYSE: BMY) has released its financial report for the...

Company

Pfizer Announces Leadership Shake-Up with Focus on Oncology R&D

Fineline Cube Jul 28, 2023

Pfizer Inc., (NYSE: PFE) has announced significant changes in its Research and Development (R&D) leadership....

Company

Roche Group’s H1 2023 Financial Report: Pharmaceuticals Grow While Diagnostics Dip

Fineline Cube Jul 28, 2023

Swiss pharmaceutical giant Roche Group (SWX: ROG) has released its half-yearly financial report for 2023,...

Company Drug

MSD’s V116 Vaccine Shows Superior Immune Response in Phase III Trials

Fineline Cube Jul 28, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has revealed positive topline results from two Phase...

Company Deals

Pharmaniaga Berhad and CSPC Pharmaceutical Group Broaden Collaboration in Pharma and Biopharma

Fineline Cube Jul 27, 2023

Malaysia-based pharmaceutical company Pharmaniaga Berhad has announced the signing of a comprehensive collaboration with China’s...

Company

Thermo Fisher Scientific Reports Q2 2023 Revenue Dip, Adjusts Full-Year Forecast

Fineline Cube Jul 27, 2023

US-based life sciences giant Thermo Fisher Scientific Inc. (NYSE: TMO) has released its financial results...

Company Deals

AbbVie and Calibr Announce Strategic Collaboration to Advance Preclinical Research

Fineline Cube Jul 27, 2023

AbbVie (NYSE: ABBV) and US-based Calibr, the nonprofit drug discovery division of San Diego research...

Company

GSK Reports 4% YOY Sales Growth in Q2 2023, Upgrades Full-Year Guidance

Fineline Cube Jul 27, 2023

UK-based pharmaceutical giant GlaxoSmithKline plc (GSK, NYSE: GSK) has released its financial report for the...

Company Drug

Everest Medicines Launches Xerava Antibiotic in China, Marking Commercial Milestone

Fineline Cube Jul 27, 2023

Everest Medicines (HKG: 1952) has announced the commercial launch of its Xerava (eravacycline) antibiotic in...

Company Drug

Jiangsu Recbio’s Shingles Vaccine REC610 Accepted for Review by China’s NMPA

Fineline Cube Jul 27, 2023

Jiangsu Recbio Technology Co., Ltd, a China-based company, has announced that the National Medical Products...

Company Deals

Mirxes Holding Company Secures USD 50 Million in Series D Financing for RNA Technology

Fineline Cube Jul 27, 2023

Mirxes Holding Company Ltd, a Singapore-headquartered RNA technology company specializing in blood-based miRNA test kit...

Company Drug

Shanghai Henlius Completes Phase I/II Study for Anti-VEGF mAb HLX04-O in Wet AMD

Fineline Cube Jul 27, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) subsidiary, Shanghai Henlius Biotech, Inc....

Company Deals

Innovent Biologics’ Altruist Biologics Partners with Longbio Pharma in RMB 500 Million Deal

Fineline Cube Jul 27, 2023

Altruist Biologics, the Contract Development and Manufacturing Organization (CDMO) unit of China-based Innovent Biologics, Inc. (HKG:...

Company Drug

SSY Group Ltd Receives NMPA Approval for Stiripentol Dry Suspension for Dravet Syndrome

Fineline Cube Jul 27, 2023

China-based SSY Group Ltd (HKG: 2005) has announced that it has received marketing approval from...

Company Drug

Novo Nordisk’s Turoctocog Alfa Pegol for Hemophilia A Accepted for Review by China’s CDE

Fineline Cube Jul 26, 2023

The Center for Drug Evaluation (CDE) in China has indicated on its website that the...

Posts pagination

1 … 542 543 544 … 711

Recent updates

  • Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval
  • Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia
  • ImmuneOnco’s IMM0306 Wins FDA IND Clearance for SLE — World’s First CD47/CD20 Bispecific in Clinic Enters U.S.
  • North China Pharma Wins NMPA Clinical Trial Approval for World-First Hexavalent Norovirus Vaccine Candidate
  • Simcere H1 Earnings Surge as Neuroscience Revenue Jumps 60.9% and Profit Rises 37.9%
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval

Company Drug

Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia

Company Drug

ImmuneOnco’s IMM0306 Wins FDA IND Clearance for SLE — World’s First CD47/CD20 Bispecific in Clinic Enters U.S.

Company Drug

North China Pharma Wins NMPA Clinical Trial Approval for World-First Hexavalent Norovirus Vaccine Candidate

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.